

WEST Search History for Application 10506406

Creation Date: 2009042014:01

Query	DB	Op.	Plur.	Thes.	Date
(PAI-1) and (mutant)	USPT	OR	YES		08-18-2008
((PAI-1) and (mutant)) and (A3 strand)	USPT	OR	YES		08-18-2008
((PAI-1) and (mutant)) and (A4 strand)	USPT	OR	YES		08-18-2008
((PAI-1) and (mutant)) and (A5 strand)	USPT	OR	YES		08-18-2008
((PAI-1) and (mutant) and (A5 strand)) and ((PAI-1) and (mutant) and (A4 strand))	USPT	OR	YES		08-18-2008
((PAI-1) and (mutant) and (A3 strand)) and ((PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand))	USPT	OR	YES		08-18-2008
((PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand)) and (helix D)	USPT	OR	YES		08-18-2008
swiercz.in.	PGPB	OR	YES		08-18-2008
((PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand) and (helix D)) and (sulfhydryl group)	USPT	OR	YES		08-18-2008
(disulfide bridge) and ((PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand) and (helix D) and (sulfhydryl group))	USPT	OR	YES		08-18-2008
swiercz.in.	USPT	OR	YES		08-18-2008
(swiercz.in.) and ((disulfide bridge) and (PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand) and (helix D) and (sulfhydryl group))	USPT	OR	YES		08-18-2008
((disulfide bridge) and (PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand) and (helix D) and (sulfhydryl group)) and (plasminogen activator inhibitor type-1)	USPT	OR	YES		08-18-2008
(cysteine or met) and ((disulfide bridge) and (PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand) and (helix D) and (sulfhydryl group) and (plasminogen activator inhibitor type-1))	USPT	OR	YES		08-18-2008
	USPT	OR	YES		08-18-2008

(cysteine) and ((disulfide bridge) and (PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand) and (helix D) and (sulfhydryl group) and (plasminogen activator inhibitor type-1))					
((cysteine) and (disulfide bridge) and (PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand) and (helix D) and (sulfhydryl group) and (plasminogen activator inhibitor type-1)) and (position 31)	USPT	OR	YES		08-18-2008
((cysteine) and (disulfide bridge) and (PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand) and (helix D) and (sulfhydryl group) and (plasminogen activator inhibitor type-1)) and (position 31 or 355 or 347 or 192 or 197 or 97)	USPT	OR	YES		08-18-2008
((cysteine) and (disulfide bridge) and (PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand) and (helix D) and (sulfhydryl group) and (plasminogen activator inhibitor type-1) and (position 31 or 355 or 347 or 192 or 197 or 97)) and (longer in vivo half-life)	USPT	OR	YES		08-18-2008
((cysteine) and (disulfide bridge) and (PAI-1) and (mutant) and (A3 strand) and (PAI-1) and (mutant) and (A5 strand) and (PAI-1) and (mutant) and (A4 strand) and (helix D) and (sulfhydryl group) and (plasminogen activator inhibitor type-1) and (position 31 or 355 or 347 or 192 or 197 or 97) and (longer in vivo half-life)) and (prolonged half-life)	USPT	OR	YES		08-18-2008
PAI-1	USPT	OR	YES		02-26-2009
(PAI-1) and (disulfide)	USPT	OR	YES		02-26-2009
(PAI-1 and (disulfide)) and (introduce disulfide bridges)	USPT	OR	YES		02-26-2009
(PAI-1 and (disulfide) and (introduce disulfide bridges)) and (urokinase activity)	USPT	OR	YES		02-26-2009
(PAI-1 and (disulfide) and (introduce disulfide bridges) and (urokinase activity)) and (sulfhydryl group)	USPT	OR	YES		02-26-2009
(PAI-1 and (disulfide) and (introduce disulfide bridges) and (urokinase activity) and (sulfhydryl group)) and (position 31 or position 192)	USPT	OR	YES		02-26-2009
(PAI-1 and (disulfide) and (introduce disulfide bridges) and (urokinase activity) and (sulfhydryl group) and (position 31 or position 192)) and (position 347 or 97)	USPT	OR	YES		02-26-2009
(PAI-1 and (disulfide) and (introduce disulfide bridges) and (urokinase activity) and (sulfhydryl group) and (position 31 or	USPT	OR	YES		02-26-2009

postion 192) and (posiiton 347 or 97)) and (longer half-life)					
(PAI-1 and (disulfide) and (introduce disulfide bridges) and (urokinase activity) and (sulfhydryl group) and (position 31 or postion 192) and (posiiton 347 or 97) and (longer half-life)) and (invovo half-life)	USPT	OR	YES		02-26-2009
swiercz.in.	USPT	OR	YES		02-26-2009
swiercz.in.	PGPB	OR	YES		02-26-2009
(PAI-1)	USPT	OR	YES		04-20-2009
((PAI-1)) and (mutant)	USPT	OR	YES		04-20-2009
((PAI-1) and (mutant)) and (sulfhydryl group)	USPT	OR	YES		04-20-2009
((PAI-1) and (mutant) and (sulfhydryl group)) and (cysteine)	USPT	OR	YES		04-20-2009
((PAI-1) and (mutant) and (sulfhydryl group) and (cysteine)) and (disulfide bridges)	USPT	OR	YES		04-20-2009
((PAI-1) and (mutant) and (sulfhydryl group) and (cysteine) and (disulfide bridges)) and (position 31 or 97 or 192 or 347 or 355)	USPT	OR	YES		04-20-2009
swiercz.in.	PGPB	OR	YES		04-20-2009
selman.in.	PGPB	OR	YES		04-20-2009
jankun.in.	PGPB	OR	YES		04-20-2009
(jankun.in.) and (selman.in.)	PGPB	OR	YES		04-20-2009